Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery
Launched by EYED PHARMA · Jun 17, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to deliver a medicine called Timolol, which is already used to treat glaucoma and high eye pressure, by placing a small implant inside the eye during cataract surgery. The main goal is to see how safe this implant is at three different dose levels and how well the body tolerates it. Researchers will also check how the implant is placed and removed, whether the medicine enters the bloodstream, and if it helps lower the pressure inside the eye.
People who might be eligible for this study are adults with open-angle glaucoma or ocular hypertension (high pressure in the eye) who also have cataracts and are scheduled for cataract surgery. Participants need to be in good overall health and able to give informed consent. The study does not include people who are allergic to certain heart medications called beta-blockers, those using other eye medicines that could affect vision or pupil size, or those with other serious eye conditions. If you join the trial, you can expect to have the implant placed during your cataract surgery and be closely monitored to see how well the implant works and how safe it is for your eye and overall health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Capable of giving signed informed consent.
- • In good general and mental health without ongoing clinically significant abnormalities in medical history.
- • Open-angle glaucoma or ocular hypertension and age-related cataract eligible for intra-capsular IOL placement.
- • successful, uncomplicated cataract surgery
- Exclusion Criteria:
- • Subjects with a history of hypersensitivity or contraindications to β- blockers.
- • Participants using any systemic or topical drug known to interfere with visual performance, pupil dilation, or iris structure
- • Significant risks caused by washout of ocular hypotensive medications.
- • Clinically significant ocular pathology other than OHT, glaucoma and cataract
About Eyed Pharma
Eyed Pharma is a leading clinical trial sponsor specializing in the development and commercialization of innovative ophthalmic therapies. With a commitment to advancing eye health, Eyed Pharma leverages cutting-edge research and state-of-the-art technology to address unmet medical needs in the field of vision care. The organization collaborates with healthcare professionals and regulatory bodies to ensure rigorous compliance and ethical standards throughout the clinical trial process. By prioritizing patient safety and efficacy, Eyed Pharma aims to deliver transformative solutions that enhance the quality of life for individuals suffering from various ocular conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Panama City, , Panama
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported